<DOC>
	<DOCNO>NCT02410785</DOCNO>
	<brief_summary>The polyglucosamine , specification L112 medical device clinical trial use weight reduction overweight obese participant . The rationale study show overweight reduce take 2 time daily 2 tablet main meal high fat content .</brief_summary>
	<brief_title>Efficacy Polyglucosamine Weight Loss</brief_title>
	<detailed_description>To comparable diet condition , participant group follow recommendation German clinical practice guideline management prevention obesity . One group take polyglucosamine tablet group placebo tablet least 24 week . It known , polyglucosamine fat binder act physical-chemical manner , positive charge fiber bound negative charge dietary fat complex unable pas gut wall body naturally excrete , hence energy available . Therefore , medical device show measurable reduction body weight .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>BMI &gt; 26 &lt; 45 waist circumference 88 cm woman great 102 men . pregnancy breastfeeding , alcohol abuse , drug abuse drug addiction , inability fulfill criterion trial protocol , cancer disease , malignant tumor , preexistence chronic intestinal disease know hypersensitivity reaction crustacean</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>obesity ,</keyword>
	<keyword>body weight ,</keyword>
	<keyword>overweight ,</keyword>
	<keyword>weight loss ,</keyword>
	<keyword>polyglucosamine ,</keyword>
	<keyword>L112</keyword>
	<keyword>caloric restriction</keyword>
	<keyword>physical activity</keyword>
</DOC>